Showing results (371-380 of 504) with videos related to
Sort By:
Pageof 51
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2011
Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteinsChristiane Querfeld, Steven T Rosen, Joan Guitart, et al.Cancer & Metabolism|November 28, 2013
Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myelomaJavelin C Cheng, Samuel K McBrayer, Cristian Coarfa, et al.The British Journal of Dermatology|February 23, 2022
Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcomeCosimo Di Raimondo, Belen Rubio-Gonzalez, Joycelynne Palmer, et al.Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 24, 1999
Assessment of coagulation system activation using spot urine measurementsS E Lind, S Goldshteyn, C P Barry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myelomaKyriakos P Papadopoulos, David S Siegel, David H Vesole, et al.The British Journal of Dermatology|August 24, 2021
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case seriesN A Trum, J Zain, X U Martinez, et al.Cell Reports|October 28, 2024
CD84 as a therapeutic target for breaking immune tolerance in triple-negative breast cancerStav Rabani, Emine Gulsen Gunes, Martin Gunes, et al.Journal of Medicinal Chemistry|November 1, 1990
Synthesis, in vitro binding profile, and central nervous system penetrability of the highly potent 5-HT3 receptor antagonist [3H]-4-(2-methoxyphenyl)-2-[4(5)-methyl-5(4)-imidazolylmethyl]thiazoleT Rosen, T F Seeger, S McLean, et al.Journal of Medicinal Chemistry|October 1, 1990
Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonistsT Rosen, A A Nagel, J P Rizzi, et al.Cancer Biotherapy|January 1, 1993
A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1T Kuzel, S T Rosen, A M Zimmer, et al.Pageof 51